Efficacy and Safety of SYH2069 Injection in Obese Participants Without Diabetes.

Prior treatment

• 3\. Use of any medications or products that alter body weight and interfere with weight assessment within 3 months prior to screening;
• 4\. Prior bariatric surgery or weight-loss interventions, or plan to receive any bariatric surgery or weight-loss intervention during the trial.
• 5\. History of or known hypersensitivity to any active ingredient or excipient of the investigational product; known allergic diathesis; or severe allergic diseases present at screening.
• 7\. Prior history of acute or chronic pancreatitis or pancreatic injury; history of acute gallbladder disease within 1 year prior to screening; .
• 8\. History of severe cardiovascular or cerebrovascular events within 6 months prior to screening.
• 9\. Prior severe respiratory, central nervous system or psychiatric disorders; any suicide attempts within the past 2 years, or suicidal ideation within 3 months prior to screening or during screening;
• 13\. History of alcohol abuse, substance misuse or illicit drug use prior to screening
• 14\. Severe trauma, severe or acute infection occurring within 3 months prior to screening or between screening and randomization
• 15\. Prior clinical trial exposure to study drug within 90 days pre-screening or 5 drug half-lives, whichever is longer.

Other illness

• 1\. Participants with a history of diabetes mellitus or hypoglycemic episodes;
• 2\. Participants with obesity caused by known single-gene mutations, other medical conditions, or medications, or weight gain not resulting from increased adipose tissue mass;
• 6\. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN-2).
• 10\. Any treated or untreated malignancy diagnosed from 5 years before screening through randomization (clinically cured basal cell carcinoma or carcinoma in situ are exempted).
• 17\. Any other conditions that, in the investigator's judgment, render the participant unsuitable for this study.

Lab values

• 11\. Clinically significant hematological diseases, hemolytic or red blood cell disorders, or baseline conditions that interfere with HbA1c measurement at screening or randomization.

Other

• 12\. Participants with inadequately controlled blood pressure
• 16\. Pregnancy or lactation; fertile male or female participants and their partners who fail to use effective contraception throughout the trial and for 3 months following the end of treatment.

• 1.Male or female participants, 18-65 years of age at the time of signing informed consent;
• 2.At screening visit, 28.0 kg/m\^2≤BMI≤ 40.0 kg/m\^2;
• 3.Maintained consistent diet and exercise habits with stable body weight within the 12 weeks prior to screening (self-reported weight variation \<5%).;
• 4.Able to understand and comply with trial procedures, voluntarily participate in the trial, and provide written informed consent (ICF).